TNFRSF10A
Tumor necrosis factor receptor superfamily member 10A
As of the edition of 20 October 2026, TNFRSF10A (tumor necrosis factor receptor superfamily member 10A, UniProt O00220) has 2 drugs tested at it and 4 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O00220
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 1
- Disease areas
- Cancer; Digestive system; Lungs and airways; Blood and lymph; Immune system; Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 12
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Mapatumumab | Went quiet | Phase 2 | none listed |
| Dulanermin | Went quiet | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Total on the list | 4 |
The other 1 company at TNFRSF10A
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at TNFRSF10A, ranked, with the facts behind eachRequest access. Nothing is shown until you do.